Liquidia Corp
LQDA · XNASCIK 1819576fmd_0TG6FC6Q19P732KQ5BSHA6G266Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 28 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 8 | 1 | 13 | 16 | 17 | 14 | 158 |
| Cost of revenue | – | 0 | 3 | 3 | 3 | 6 | – |
| Gross profit | – | 1 | 10 | 13 | 15 | 8 | – |
| Research and development | 40 | 32 | 21 | 19 | 43 | 48 | 39 |
| Selling, general and administrative | – | – | – | – | 45 | 82 | 157 |
| Operating income | (47) | (59) | (34) | (39) | (73) | (121) | (51) |
| Interest expense | 1 | 1 | 1 | 2 | 6 | 15 | 24 |
| Interest and investment income | 1 | 0 | 0 | 1 | 3 | 8 | 7 |
| Other non-operating income (expense) | (1) | (1) | (1) | (2) | (5) | (7) | (18) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (48) | (60) | (35) | (41) | (79) | (128) | (69) |